| Items | Content |
|---|---|
| Year | 2025 |
| Awards |
|
| Name of Entry | SLOPE device |
| Description |
Entoptica introduces an innovative tool for age-related macular degeneration (AMD) screening: the Structured Light Observation Perception and Evaluation (SLOPE) system. |
Entoptica introduces an innovative tool for age-related macular degeneration (AMD) screening: the Structured Light Observation Perception and Evaluation (SLOPE) system. SLOPE enables early detection of macular degeneration through a quick, two-minute test that does not require pupil dilation, ensuring a comfortable experience for patients. Compared to traditional Optical Coherence Tomography (OCT) devices, SLOPE is significantly more affordable, with a price point of USD 100,000 versus USD 300,000 for OCT. Its compact and portable design makes it ideal for use in clinics as well as rural or remote settings. The effectiveness and reliability of SLOPE have been demonstrated in clinical studies involving 200 participants at both Hong Kong Science Park and the University of Waterloo in Canada.
The application from Entoptica Limited for its SLOPE device presents a strong case based on its technological innovation and potential societal benefit. The entry details a novel application of quantum technology in vision sciences, designed for the early detection of Age-related Macular Degeneration (AMD). The proposed solution aims to provide a rapid, non-invasive, and more affordable screening method compared to existing standards. By improving the accessibility of early diagnostics, the technology has the potential to improve patient outcomes for a large global population and may help lower barriers to advanced healthcare, particularly in underserved communities.
From a commercial and operational standpoint, the submission outlines a viable business case. It presents a clear strategy to enter the substantial AMD diagnostics market, leveraging a competitive price point and a portable device design as key differentiators for international market penetration. The project’s credibility is supported by its foundation in scientific research, with clinical studies conducted at recognized institutions providing validation for the device’s stability and reliability. The application demonstrates a commitment to quality assurance processes and a clear assessment of operational risks, indicating a strong capacity for execution. The entry shows strength across the key criteria of innovation, market potential, quality, and impact.